Disease: Thrombotic thrombocytopenic purpura- acquired
- A 'needle in a haystack': Drug-induced thrombotic thrombocytopenic purpura-Association or causality?
- A case of acquired thrombotic thrombocytopenic purpura induced by acute severe hepatitis E: successfully treated by plasma exchange and rituximab
- A case of systemic lupus erythematosus having concurrent Evans syndrome and acquired thrombotic thrombocytopenic purpura
- A Case of Thrombotic Thrombocytopenic Purpura and ST-Elevation Myocardial Infarction: An Unusual Correlation
- A case of thrombotic thrombocytopenic purpura associated with COVID-19
- A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura
- A Fluorescence Cross-Correlation-Spectroscopy-Based Immunoassay for Rapid, Selective, and Accurate Protein Sizing in Human Plasma, Applied to the von Willebrand Factor
- A robust response to high-dose plasma, prednisolone, and rituximab in an infant with acquired thrombotic thrombocytopenic purpura
- A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura
- Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature Review
- Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
- Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system
- Acquired thrombotic thrombocytopenic purpura during durvalumab monotherapy for non-small cell lung cancer
- Acquired Thrombotic Thrombocytopenic Purpura in a 5-Year-old Child With Wiskott-Aldrich Syndrome
- Acquired Thrombotic Thrombocytopenic Purpura: A Rare Coincidence after COVID-19 mRNA Vaccine?
- ADAMTS13 Antibody and Inhibitor Assays
- ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology
- Adolescent acquired thrombotic thrombocytopenic purpura: An analysis of the Pediatric Health Information System database
- An Uncommon Presentation of Vasopressin-Induced Purpura Fulminans
- Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?
- Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study
- Atypical Hemolytic Uremic Syndrome in a Pregnant Patient with a Thrombomodulin Gene Variant Treated with Plasma Exchange and Eculizumab
- Benchmarking the centralized urgent plasma exchange service for patients admitted with a diagnosis of suspected acquired thrombotic thrombocytopenic purpura at a large healthcare system
- Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
- Caplacizumab in acquired thrombotic thrombocytopenic purpura: Dose adjustment based on von Willebrand factor
- Caplacizumab in acquired thrombotic thrombocytopenic purpura: Dose adjustment based on von Willebrand factor level
- Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
- Caplacizumab treatment for acquired refractory thrombotic thrombocytopenic purpura
- Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?
- Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura
- Case report: Microangiopathic hemolytic anemia and thrombocytopenia in a child with Brucella infection
- Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab
- Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura
- Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura
- Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
- Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
- Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia
- Development of a novel aptamer blocking the interaction between the VWF A1 domain and platelet GP Ib for the treatment of arterial thrombosis
- Diabetic Ketoacidosis Complicated by Thrombotic Thrombocytopenic Purpura: A Rare Association
- Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data
- Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia
- Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
- Emerging mechanisms to modulate VWF release from endothelial cells
- Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab
- Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2
- Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura
- Functional autoantibodies: Definition, mechanisms, origin and contributions to autoimmune and non-autoimmune disorders
- Hereditary thrombotic thrombocytopenic purpura acquired through liver transplantation: A case report
- High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP
- HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination
- Humanized anti CD-20 as an alternative in chronic management of relapsing thrombotic thrombocytopenic microangiopathy resistant to rituximab due to anti chimeric antibody
- Identification of ADAMTS13 Inhibitors in Acquired TTP
- Identify the influences of systemic lupus erythematosus on acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura using comprehensive bioinformatics analysis
- Idiopathic TTP in the Middle East: Epidemiology and clinical outcomes in infection associated episodes
- Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?
- Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments - an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES)
- Immune-Mediated Platelet Activation in COVID-19 and Vaccine-Induced Immune Thrombotic Thrombocytopenia
- International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13
- Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut
- Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children
- Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era
- N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study
- NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura
- Non-ST-Segment Elevation Myocardial Infarction As Initial Thrombotic Event of Thrombotic Thrombocytopenic Purpura: A Rare Challenging Case
- Novel treatment strategies for acquired thrombotic thrombocytopenic purpura
- Pregnancy-associated thrombotic thrombocytopenic purpura complicated by Sjögren's syndrome and non-neutralising antibodies to ADAMTS13: a case report
- Pseudo-Thrombotic Thrombocytopenic Purpura Due to Severe Vitamin B12 Deficiency: A Case Report
- Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: Case series
- Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A single-center with homogeneous treatment experience
- Real-world Experience of Caplacizumab for Adolescents in the First-line Setting: Case Reports
- Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children
- Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell trait successfully treated with caplacizumab
- Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus
- Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review
- Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura
- Role of the PLASMIC Score in the Management of Thrombotic Thrombocytopenic Purpura
- Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period
- Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review
- Semi-selective plasma filtration applied to the treatment of acquired thrombotic thrombocytopenic purpura following bnt162b2 administration
- Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era
- Severe rituximab-induced pneumonitis in an immunocompromised child with acquired thrombotic thrombocytopenic purpura
- Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a 'subclinical' TTP state
- Successful Treatment of Acquired Thrombotic Thrombocytopenic Purpura With Caplacizumab Combined With Plasma Exchanges and Immune Suppression in 3 Children
- Successful Treatment With Bortezomib for Refractory and Complicated Acquired Thrombotic Thrombocytopenic Purpura in an Adolescent Girl
- Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis
- Systemic lupus erythematosus presenting as thrombotic thrombocytopaenic purpura in a child: a diagnostic challenge
- The frontline of TMA management
- The Role of the von Willebrand Factor Collagen-Binding Assay (VWF:CB) in the Diagnosis and Treatment of von Willebrand Disease (VWD) and Way Beyond: A Comprehensive 36-Year History
- Therapeutic plasma exchange (TPE) as a plausible rescue therapy in severe vaccine-induced immune thrombotic thrombocytopenia
- Thrombotic thrombocytopenic purpura developed after pegylated interferon treatment for hepatitis B infection
- Thrombotic thrombocytopenic purpura developed during the conservative treatment of anti-phospholipase A<sub>2</sub> receptor antibody-positive idiopathic membranous nephropathy: a case report
- Thrombotic thrombocytopenic purpura following ChAdOx1 nCov-19 vaccination: A case report
- Thrombotic thrombocytopenic purpura in caplacizumab era - An individualized approach
- Thrombotic thrombocytopenic purpura in pediatrics. A case report
- Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond
- Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review
- Two ischemic stroke events within 48 h: a case report of an unusual presentation of thrombotic thrombocytopenic purpura
- Unusual presentation of acquired thrombotic thrombocytopenic purpura (TTP) versus catastrophic antiphospholipid syndrome in a patient with Moya-Moya disease, case report, and literature review
- Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085-3092
- Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab